Ramucirumab plus docetaxel improves progression-free survival in urothelial cancer

(European Society for Medical Oncology) Ramucirumab plus docetaxel improves progression-free survival in patients with advanced or metastatic urothelial cancer who have progressed on platinum-based chemotherapy, according to late-breaking results from the phase III RANGE trial presented today at the ESMO 2017 Congress in Madrid to be published in The Lancet.

https://www.eurekalert.org/pub_releases/2017-09/esfm-rpd091017.php

Source: EurekAlert! - Cancer - September 10, 2017 Category: Cancer & Oncology Source Type: news